The year has changed the hope for better moments now falls on the vaccine. In Portugal, 70 thousand doses have already been administered and the process is then underway. However, doubts arose regarding the effectiveness of Pfizer-BioNTech regarding the new strain of the COVID-19 virus.

A recent study suggests that the vaccine to be administered in Portugal is effectively effective against the new strain of the virus.

Pfizer BioNTech vaccine.

Pfizer-BioNTech vaccine effective against the new strain

A few weeks ago, the United Kingdom alerted the world to a new strain of the virus that causes COVID-19. This, after vaccines are being developed and several countries have already acquired that of Pfizer-BioNTech.

As a result, the concern returned and, globally, the question arose about the vaccine's effectiveness in relation to the new strain that appeared in the United Kingdom.

Although it was said that the vaccine could be effective, there were still no certainties. So, they are now the result of new research that suggests that the vaccine to be administered in Portugal can effectively protect against the new, apparently more infectious variants.

Pfizer BioNTech vaccine.

Vaccine readjustments are not out of the question

As reported, these variants carry multiple mutations, but share one that scholars believe is the reason they are more infectious. So, the N501Y is a slight change in one point of the spike protein that lines the virus.

To see if your vaccine would be effective, recognizing this change and fighting it, the Pfizer joined researchers from University of Texas Medical Branch, in Galveston, to do laboratory tests.

According to the study, they used blood samples from 20 people who received the vaccine from Pfizer-BioNTech. Subsequently, the receptor antibodies successfully fought the virus in laboratory dishes.

It was a very reassuring discovery that at least this mutation, which was one of the ones that most worried people, does not seem to be a problem.

Revealed Philip Dormitzer, scientific head of Pfizer.

Although the study is still preliminary and has not been reviewed by experts, Anthony Fauci, the leading American infectious disease specialist, recently clarified that vaccines are designed to recognize multiple parts of the virus' spike protein. As such, they are unlikely to be effective against a new strain.

Even so, viruses inherently undergo small changes as they spread and, therefore, it is necessary to test and, if necessary, readjust the vaccine.

Read too:

Leave a Reply

Your email address will not be published. Required fields are marked *